Table 1.
Baseline characteristics of VL–HIV co-infected patients diagnosed at the Metema district hospital (2010–2014) and the Gondar Leishmania research and treatment center (2010–2016), northwest Ethiopia
| Metema (N = 58) median (IQR) or n (%) | Gondar (N = 112) median (IQR) or n (%) | |
|---|---|---|
| Age, years; median (IQR) | 30 (27–36) | 32 (29–37) |
| Missing | 0 | 2 |
| Male sex, n (%) | 56 (98) | 109 (98) |
| Missing | 0 | 1 |
| TB at enrolment, n (%) | 7 (12) | 6 (5) |
| VL episode before study, n (%) | 6 (10) | 22 (18) |
| Total number of VL episodes during study period, n (%) | ||
| 1 | 52 (89) | 86 (70) |
| 2 | 5 (9) | 17 (14) |
| 3 or more | 1 (2) | 9 (7) |
| Treatment of current episode of VL, n (%) | ||
| SSG | 45 (78) | 55 (49) |
| SSG + PM | – | 11 (10) |
| AmBisome | 2 (3) | 26 (23) |
| AmBisome + MF | – | 12 (11) |
| Other | – | 7 (6) |
| UK | 11 (19) | 1 (1) |
| ART treatment, n (%) | 22 (78) | 84 (75) |
| TDF based | 17 (77) | 59 (70) |
| AZT based | 3 (14) | 17 (20 |
| D4T based | 2 (9) | 6 (7) |
| Other | 0 (0) | 2 (2) |
AZT = zidovudine; D4T = stavudine; IQR = interquartile range; MF = miltefosine; PM = paromomycin; SSG = sodium stibugluconate; TB = tuberculosis; TDF = tenofovir; UK = unknown; VL = visceral leishmaniasis.